Connect with us

Hi, what are you looking for?

Investing

Nektar Regains Rezpegaldesleukin Rights as Eli Lilly Deal Ends >NKTR

Published

By Colin Kellaher

Nektar Therapeutics on Thursday said it would regain full rights to rezpegaldesleukin from partner Eli Lilly & Co., which is ending a licensing agreement following the failure of the compound in a Phase 2 study in systemic lupus erythematosus.

San Francisco-based Nektar said it plans to work quickly to initiate a Phase 2b…

Read the full article here

In this article:
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

News

Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript

Follow Play Earnings CallPlay Earnings Call Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs...

7 days ago

Videos

Softbank sells entire stake in Nvidia, the health of the AI trade, flight cancellations mount

Watch full video on YouTube

6 days ago

Videos

Why beef prices are out of control in the U.S.

Watch full video on YouTube

7 days ago

Videos

Bill to end shutdown moves to House, CoreWeave cuts full-year sales outlook

Watch full video on YouTube

7 days ago